Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

References 79

1. 1.

   Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):1-18.

   Not in our library10.1038/nature22071

2. 2.

   Opdualag summary of product characteristics.

   Not in our library

3. 3.

   Ewen T, Husain A, Stefanos N, et al. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma. Br J Dermatol. 2024;190(4):549-558.

   Not in our library10.1093/bjd/ljad459

4. 4.

   Marchetti MA, Coit DG, Dusza SW, et al. Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(9):953-962.

   Not in our library10.1001/jamadermatol.2020.1731

5. 5.

   Meyer S, Fuchs TJ, Bosserhoff AK, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One. 2012;7(6):e38222.

   Not in our library10.1371/journal.pone.0038222

6. 6.

   Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2023;182:155-162.

   Not in our library10.1016/j.ejca.2022.12.021

7. 7.

   Kashani-Sabet M, Leachman SA, Stein JA, et al. Early detection and prognostic assessment of cutaneous melanoma: consensus on optimal practice and the role of gene expression profile testing. JAMA Dermatol. 2023;159(5):545-553.

   Not in our library10.1001/jamadermatol.2023.0127

8. 8.

   Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. Lancet. 2023;402(10400):485-502.

   Not in our library10.1016/s0140-6736(23)00821-8

9. 9.

   Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297(12):627-630.

   Not in our library10.1056/nejm197709222971202

10. 10.

    Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978;41(3):948-956.

    Not in our library10.1002/1097-0142(197803)41:3<948::aid-cncr2820410324>3.0.co;2-z

11. 11.

    Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224(3):255-263.

    Not in our library10.1097/00000658-199609000-00002

12. 12.

    Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793-796.

    Not in our library10.1016/s0140-6736(97)08260-3

13. 13.

    Gershenwald JE, Scolyer RA, Hess KR, Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 2017;563-586.

    Not in our library

14. 14.

    Garbe C, Keim U, Amaral T, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol. 2022;40(32):3741-3749.

    Not in our library10.1200/jco.22.00202

15. 15.

    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.

    Not in our library10.3322/caac.21409

16. 16.

    Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol. 2024;42(14):1619-1624.

    Not in our library10.1200/jco.23.02355

17. 17.

    Kirkwood JM, Weber J, Hoeller C, et al. Adjuvant nivolumab versus placebo in resected stage IIB/C melanoma: update on CheckMate 76K. 2023.

    Not in our library

18. 18.

    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.

    Not in our library10.1200/jco.2009.23.4799

19. 19.

    Amaral T, Nanz L, Stadler R, et al. Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB. Eur J Cancer. 2024;201:113912.

    Not in our library10.1016/j.ejca.2024.113912

20. 20.

    Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517-527.

    Not in our library10.1200/jco.22.00533

21. 21.

    Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845-1855.

    Not in our library10.1056/nejmoa1611299

22. 22.

    Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352-3361.

    Not in our library10.1158/1078-0432.ccr-22-3145

23. 23.

    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824-1835.

    Not in our library10.1056/nejmoa1709030

24. 24.

    Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022;1(11):EVIDoa2200214.

    Not in our library10.1056/evidoa2200214

25. 25.

    Grossmann KF, Othus M, Patel SP, et al. Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12(3):644-653.

    Not in our library10.1158/2159-8290.cd-21-1141

26. 26.

    Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 2022;400(10358):1117-1129.

    Not in our library10.1016/s0140-6736(22)01654-3

27. 27.

    NCCN Clinical Practice Guidelines in Oncology Melanoma: Cutaneous. 2024.

    Not in our library

28. 28.

    Weber JS, Khattak MA, Carlino MS, et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. J Clin Oncol. 2024;42(suppl 17):LBA9512.

    Not in our library

29. 29.

    Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4):510-520.

    Not in our library10.1016/s1470-2045(18)30106-2

30. 30.

    Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.

    Not in our library10.1056/nejmoa1708539

31. 31.

    Long GV, Hauschild A, Santinami M, et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2024;391(18):1709-1720.

    Not in our library10.1056/nejmoa2404139

32. 32.

    Long GV, Blank CU, Amaria RN, et al. LBA41 Long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Ann Oncol. 2024;35:S1232.

    Not in our library

33. 33.

    Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813-823.

    Not in our library10.1056/nejmoa2211437

34. 34.

    Patel S, Othus M, Prieto V, et al. LBA6 Neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801. Ann Oncol. 2022;33(suppl 7):S1408.

    Not in our library

35. 35.

    Patel S, Othus M, Wright P, et al. LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. Ann Oncol. 2023;34(suppl 2):S1288.

    Not in our library

36. 36.

    Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696-1708.

    Not in our library10.1056/nejmoa2402604

37. 37.

    Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multi-centre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948-960.

    Not in our library10.1016/s1470-2045(19)30151-2

38. 38.

    Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized responsedirected surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178-1188.

    Not in our library10.1038/s41591-022-01851-x

39. 39.

    Hauschild A, Hassel JC, Ziemer M, et al. Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases. J Clin Oncol. 2024;42(suppl 17):LBA9501.

    Not in our library

40. 40.

    Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021;27(10):1789-1796.

    Not in our library10.1038/s41591-021-01510-7

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.